# A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

Study · id `cardio:ct-nct01105975` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01105975](<https://clinicaltrials.gov/study/NCT01105975>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01105975

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 398 participants.

## Technical summary

Registry record NCT01105975. Randomized; quadruple masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2011-06 (actual). Results posted on 2018-03-22.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 398 participants (enrolled count; ClinicalTrials.gov record NCT01105975, source copy `cardio:ctgov-nct01105975-2018-03-22`, retrieved 2026-10-31)
- Start date: 2010-04 (registry gives no type) (ClinicalTrials.gov record NCT01105975, source copy `cardio:ctgov-nct01105975-2018-03-22`, retrieved 2026-10-31)
- Primary completion: 2011-06 (actual) (ClinicalTrials.gov record NCT01105975, source copy `cardio:ctgov-nct01105975-2018-03-22`, retrieved 2026-10-31)
- Completion: 2011-06 (actual) (ClinicalTrials.gov record NCT01105975, source copy `cardio:ctgov-nct01105975-2018-03-22`, retrieved 2026-10-31)
- Results first posted: 2018-03-22 (ClinicalTrials.gov record NCT01105975, source copy `cardio:ctgov-nct01105975-2018-03-22`, retrieved 2026-10-31)
- Countries: United States; Denmark; Germany; Netherlands; Poland; United Kingdom (ClinicalTrials.gov record NCT01105975, source copy `cardio:ctgov-nct01105975-2018-03-22`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01105975-2018-03-22`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
- Condition: Dyslipidemia
- Intervention (Drug): LY2484595
- Intervention (Drug): Atorvastatin
- Intervention (Drug): Simvastatin
- Intervention (Drug): Rosuvastatin
- Intervention (Drug): Placebo for LY2484595
- Intervention (Drug): Placebo for Statins
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention name matches this record: Simvastatin (`cardio:simvastatin`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial (`cardio:pubmed-22089718`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib (`cardio:pubmed-26564598`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients (`cardio:pubmed-27206939`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 67ef3ffca17aabb17a4e87beaeb9f2fa45521ca5c00f4c11aa04f3b8f5398c03
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
